Company intelligence / Profile preview

Attenua

New York, New York, United Statesprnewswire.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Attenua developed novel small-molecule therapeutics for chronic cough. Its lead candidate, ATA‑101, advanced to Phase II clinical trials targeting a new mechanism for chronic cough. The company was acquired in February 2020 by CODA Biotherapeutics, which plans to leverage these assets—including three small-molecule drugs with established safety profiles—for further development in neurological indications such as neuropathic pain and focal epilepsy.

Therapeutic areas: PulmonologyNeurology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

ATP-7200

Phase 2

Indications: Chronic cough, Refractory chronic cough

Beyond the preview

Go deeper on Attenua.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Attenua.

Explore the full profile